Рекомендуем прочитать

Buchanan, R.W., J. Kreyenbuhl, D.L. Kelly, et al. “The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements” Schizophrenia Bulletin 36 (2010): 71–93.

Cohen, C.I., and S.I. Cohen. “Potential Cost Savings from Pill Splitting of Newer Psychotropic Medications.” Psychiatric Services 51 (2000): 527–29.

Deegan, P.E., and R.E. Drake. “Shared Decision Making and Medication Management in the Recovery Process.” Psychiatric Services 57 (2006): 1636–39.

Dickerson, F.B., and A.F. Lehman. “Evidence-Based Psychotherapy for Schizophrenia.” Journal of Nervous and Mental Disease 194 (2006): 3–9.

Dixon, L.B., F. Dickerson, A.S. Bellack, et al. “The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements.” Schizophrenia Bulletin 36 (2010): 48–70.

Fenton, W.S. “Prevalence of Spontaneous Dyskinesia in Schizophrenia.” Journal of Clinical Psychiatry 61 (Suppl. 4) (2000): 10–14.

Francell, E.G., Jr. “Medication: The Foundation of Recovery.” Innovations and Research 3 (1994): 31–40.

Goren J.L., A.J. Rose, E.G. Smith, et al. “The Business Case for Expanded Clozapine Utilization.” Psychiatric Services 67 (2016): 1197–1205.

Kelly, D.L., J. Kreyenbuhl, R.W. Buchanan, et al. “Why Not Clozapine?” Clinical Schizophrenia & Related Psychoses 1 (2007): 92–95.

Leucht, S., K. Komossa, C. Rummel-Kluge, et al. “A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia.” American Journal of Psychiatry 166 (2009): 152–63.

Leucht, S., M. Tardy, K. Korhossa, et al. “Antipsychotic Drugs Versus Placebo for Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis.” Lancet 379 (2012): 2067–71.

*Opler, L.A., R.S. Laitman, A.M. Laitman, et al. Clozapine: Meaningful Recovery From Schizophrenia, order from website of teamdanielrunningforreceovery.org.

The Medical Letter on Drugs and Therapeutics (The Medical Letter, Inc.), http://secure.medicalletter.org/medicalletter.

Tandon, R., and M.D. Jibson, “Efficacy of Newer Generation Antipsychotics in the Treatment of Schizophrenia,” Psychoneuroendocrinology 28 (2003): 9–26.

Torrey, E.F., M. Knable, C. Quanbeck and J. Davis. Clozapine for Treating Schizophrenia: A Comparison of the States. Treatment Advocacy Center (Arlington, VA) 2015. http://www.treatmentadvocacycenter.org/storage/documents/clozapine-for-treating-schizophrenia.pdf

Torrey, E.F., and John Davis. “Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas.” Clinical Schizophrenia & Related Psychoses 5 (2012): 208–16.

Worst Pills, Best Pills (Public Citizen’s Health Research Group), http://worstpills.org/.

Цитируемые источники

Albert Deutsch, The Shame of the States (New York: Harcourt, Brace, 1948).

J. M. Davis, “Overview: Maintenance Therapy in Psychiatry: 1. Schizophrenia,” American Journal of Psychiatry 132 (1975): 1237–45.

S. Leucht, M. Tardy, K. Komossa, et al., “Antipsychotic Drugs Versus Placebo for Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis,” Lancet 379 (2012): 2063–71.

G. Goldstein, R.D. Sanders, S.D. Forman, et al., “The Effects of Antipsychotic Medication on Factor and Cluster Structure of Neurologic Examination Abnormalities in Schizophrenia,” Schizophrenia Research 75 (2005): 55–64.

R. Mojtabai, L. Fochtmann, S- W. Chang, et al., “Unmet Need For Mental Health Care in Schizophrenia: An Overview of Literature and New Data From a First-Admission Study,” Schizophrenia Bulletin 35 (2009): 678– 95.

M. Torniainen, E. Mittendorfor-Rutz, A. Tanksanen, et al., “Antipsychotic Treatment and Mortality in Schizophrenia,” Schizophrenia Bulletin 41 (2015): 656– 63.

J. Vermeulen, G. van Rooijen, P. Doedens, et al., “Antipsychotic Medication and Long- Term Mortalitty Risk in Patients with Schizophrenia; A Systemic Review and Meta- Analysis,” Psychological Medicine 47 (2017): 2217–18.

R. W. Buchanan, J. Kreyenbuhl, D.L. Kelly, et al., “The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements,” Schizophrenia Bulletin 36 (2010): 71–93.

S. Leucht, A. Cipriani, L. Spineli, et al., “Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple- Treatments Meta-Analysis,” Lancet 382 (2013): 951– 62.

T. Turner, “Rich and Mad in Victorian England,” Psychological Medicine 19 (1989): 29–44.

W. S. Fenton, “Prevalence of Spontaneous Dyskinesia in Schizophrenia,” Journal of Clinical Psychiatry 61 (2000) (Suppl 4): 10–14.

V. Khot and R.J. Wyatt, “Not All That Moves Is Tardive Dyskinesia,” American Journal of Psychiatry 148 (1991): 661–66.

R. Yassa and N.P.V. Nair, “A 10- Year Follow- Up Study of Tardive Dyskinesia,” Acta Psychiatrica Scandinavica 86 (1992): 262–66.

O. V. Tcheremissine, “Is Quetiapine a Drug of Abuse? Reexamining the Issue of Addiction,” Expert Opinion on Drug Safety 7 (2008): 739–48.

S. Gentile, “Antipsychotic Therapy during Early and Late Pregnancy: A Systematic Review,” Schizophrenia Bulletin 36 (2010): 518–44.

P. E. Deegan and R.E. Drake, “Shared Decision Making and Medication Management in the Recovery Process,” Psychiatric Services 57 (2006): 1636–39.

“Fluphenazine Levels – Short and Long,” Biological Therapies in Psychiatry 4 (1981): 33–34.

P. Ruiz, R.V. Varner, D.R. Small, et al., “Ethnic Differences in the Neuroleptic Treatment of Schizophrenia,” Psychiatric Quarterly 70 (1999): 163–72.

S. Leucht, R. Busch, W. Kissling, et al., “Early Prediction of Antipsychotic Nonresponse among Patients with Schizophrenia,” Journal of Clinical Psychiatry 68 (2007): 352–60.

J. A. Gallego, D.G. Robinson, S.M. Sevy, et al., “Time to Treatment Response in First- Episode Schizophrenia: Should Acute Treatment Trials Last Several Months?” Journal of Clinical Psychiatry 72 (2011): 1691–96.

J. L. Goren, A.J. Rose, E.G. Smith, et al., “The Business Case for Expanded Clozapine Utilization,” Pscyhiatric Services 67 (2016): 1197–1205.

C. Leucht, S. Heres, J.M. Kane, et al., “Oral versus Depot Antipsychotic Drugs for Schizophrenia – A Critical Systematic Review and Meta-Analysis of Randomised Long- term Trials,” Schizophrenia Research 127 (2011): 83–92.

C. Arango, I. Bombín, T. González- Salvador, et al., “Randomised Clinical Trial Comparing Oral versus Depot Formulations of Zuclopenthixol in Patients with Schizophrenia and Previous Violence,” European Psychiatry 21 (2006): 34–40.

H. Taipale, E. Mittendorfer-Rutz, K. Alexanderson, et al., “Antipsychotics and Mortality in a Nationwide Cohort of 29,823 Patients with Schizophrenia,” Schizophrenia Research. 197 (2018): 274–80.

G. Goodwin, W. Fleischhacker, C. Arango, et al., “Advantages and Disadvantages of Combination Treatment with Antipsychotics,” European Neuropsychopharmacology 19 (2009): 520–32.

D. Cauchon, “Americans Pay More; Here’s Why,” USA Today, November 10, 1999.

R. Whitaker, Anatomy of an Epidemic (New York: Crown, 2010).

S. Teferra, T. Shibre, A. Fekadu, et al., “Five- year Clinical Course and Outcome of Schizophrenia in Ethiopia,” Schizophrenia Research 136 (2012): 137–42.

A. Cohen, V. Patel, R. Thara, et al., “Questioning an Axiom: Better Prognosis for Schizophrenia in the Developing World?” Schizophrenia Bulletin 34 (2008): 229–44.

J. Moncrieff, “Does Antipsychotic Withdrawal Provoke Psychosis? Review of the